312 related articles for article (PubMed ID: 33554041)
1. Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.
Salazar AS; Rakhmankulova M; Simon LE; Toriola AT
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554041
[TBL] [Abstract][Full Text] [Related]
2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
3. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
4. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Fabian CJ; Kimler BF
Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
[TBL] [Abstract][Full Text] [Related]
5. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
6. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.
Hackshaw A; Baum M; Fornander T; Nordenskjold B; Nicolucci A; Monson K; Forsyth S; Reczko K; Johansson U; Fohlin H; Valentini M; Sainsbury R
J Natl Cancer Inst; 2009 Mar; 101(5):341-9. PubMed ID: 19244174
[TBL] [Abstract][Full Text] [Related]
8. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
Gram IT; Ursin G; Spicer DV; Pike MC
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1117-20. PubMed ID: 11700258
[TBL] [Abstract][Full Text] [Related]
9. RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell A; Ashcroft L; Fallowfield L; Eccles DM; Eeles RA; Ward A; Brentnall AR; Dowsett M; Cuzick JM; Greenhalgh R; Boggis C; Motion J; Sergeant JC; Adams J; Evans DG
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):58-66. PubMed ID: 29097444
[No Abstract] [Full Text] [Related]
10. Current concepts in breast cancer chemoprevention.
Chlebowski RT
Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
[TBL] [Abstract][Full Text] [Related]
11. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
[TBL] [Abstract][Full Text] [Related]
12. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
13. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
15. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
16. Effect of tamoxifen on breast tissue density in premenopausal breast cancer.
Slanetz PJ; Grandpre LE; Yeh ED; Kopans DB; Mendel JB
Breast J; 2004; 10(1):27-32. PubMed ID: 14717756
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
18. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
Sano M; Makino H
Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
[No Abstract] [Full Text] [Related]
19. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.
Eng-Wong J; Orzano-Birgani J; Chow CK; Venzon D; Yao J; Galbo CE; Zujewski JA; Prindiville S
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1696-701. PubMed ID: 18583470
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of breast cancer.
Castrellon AB; Glück S
Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
